MicroPort
MicroPort is a multinational medical technology company that develops and manufactures devices for cardiovascular care, orthopedics, endovascular intervention, surgical robotics and other specialties.
Last updated October 14, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
MicroPort is a China-founded multinational medical technology company headquartered in Shanghai, with major operating locations in Irvine, California, and Clamart, France. Founded in 1998 by Zhaohua Chang and a team of engineers, the company initially concentrated on interventional cardiology, producing coronary balloons, catheters and drug-eluting stents for the Chinese healthcare market. It subsequently developed into a diversified medical-device group with activities spanning coronary and peripheral intervention, structural heart disease, cardiac rhythm management, electrophysiology, neurovascular intervention, orthopedics, surgical robotics, critical care and other specialist fields. The company’s early growth was driven by domestic coronary-device development. Its Firebird and Firebird2 drug-eluting stent platforms helped establish MicroPort as a leading Chinese supplier during the 2000s, while international distribution began to expand in Asia. MicroPort completed an initial public offering on the Hong Kong Stock Exchange in September 2010 under stock code 00853.HK, providing capital for research, international commercialization and acquisitions. During the 2010s, MicroPort broadened its scope through both internal research and acquisitions. The 2014 purchase of Wright Medical’s OrthoRecon business created MicroPort Orthopedics and added hip and knee reconstruction products. A strategic collaboration with Sorin Group expanded the company into cardiac rhythm management, and MicroPort later acquired LivaNova’s CRM business in 2018, obtaining pacemakers, implantable cardioverter-defibrillators and cardiac-resynchronization products. The 2018 acquisition of Lombard Medical Technologies added endovascular stent-graft systems for aortic disease, including the Altura and Aorfix platforms. Interventional cardiology remains a central part of the group. The Firehawk coronary stent uses recessed abluminal grooves to deliver sirolimus with a biodegradable polymer and a comparatively low drug and polymer load. The company also developed Firesorb, a bioresorbable vascular scaffold, while continuing clinical and regulatory work in a field that experienced setbacks for some competing first-generation products. Other cardiovascular platforms include transcatheter aortic-valve implantation systems, electrophysiology catheters and three-dimensional navigation technologies. MicroPort has organized many activities into specialized subsidiaries, several of which obtained independent public listings. MicroPort Endovastec listed on the Shanghai Stock Exchange’s STAR Market in 2020. MicroPort CardioFlow and MicroPort MedBot listed in Hong Kong in 2021, followed by MicroPort NeuroTech in 2022 and MicroPort EverPace on the Shanghai STAR Market later in 2022. This platform structure gives individual therapeutic businesses dedicated management and capital markets access while retaining coordination within the broader MicroPort group. The group’s robotics business is represented by MicroPort MedBot, whose principal product is the Toumai multi-port laparoscopic surgical robot. Toumai is designed for minimally invasive procedures in specialties including general, thoracic, urological and gynecological surgery. MedBot has also pursued international clinical work involving remote surgery, including reported telesurgery procedures involving facilities in Angola. MicroPort’s international footprint includes research, manufacturing, regulatory and commercial operations in China, the United States, France and the United Kingdom. Its devices have been distributed in more than 90 countries, according to the supplied reference material. In 2025, the company announced a proposed integration of the CardioFlow structural-heart business with its CRM activities and reported that cumulative global shipments and implantations of its coronary stent systems had each exceeded 10 million. MicroPort therefore presents itself as a globally oriented, multi-platform medical-technology group rather than solely as a coronary-stent manufacturer.
History
MicroPort was founded in Shanghai in 1998 by Zhaohua Chang and a team of engineers. Its initial business was interventional cardiology, particularly coronary balloons, catheters and drug-eluting stents intended for the Chinese market. During the 2000s, the company introduced successive Firebird platforms and became a leading domestic supplier. It also began distributing products internationally, including in Asian markets. The company’s public-market expansion began with its September 2010 initial public offering on the Hong Kong Stock Exchange. The new capital supported product development, regulatory work and overseas growth. MicroPort continued to develop coronary technologies, including the Firehawk drug-eluting stent, which received Chinese approval in 2014 and European CE Mark approval in 2015. Its design delivers sirolimus from abluminal grooves and uses a biodegradable polymer. MicroPort also pursued Firesorb, a bioresorbable vascular scaffold, despite wider industry difficulties involving early-generation scaffolds. A major strategic shift occurred during the 2010s as MicroPort moved beyond coronary intervention. In 2014 it acquired Wright Medical’s OrthoRecon business for approximately $290 million, creating MicroPort Orthopedics and adding hip and knee reconstruction implants. The same year, it entered cardiac rhythm management through a collaboration with Sorin Group. In 2018, MicroPort acquired LivaNova’s CRM business for approximately €190 million, obtaining pacemakers, implantable cardioverter-defibrillators and cardiac-resynchronization products, with major operations in Clamart, France. It also acquired the operations of Lombard Medical Technologies in 2018, adding Altura and Aorfix endovascular stent-graft systems. MicroPort adopted a platform model in the late 2010s and early 2020s. Specialized businesses were given distinct management structures and, in several cases, access to independent public financing. MicroPort Endovastec listed in Shanghai in 2020. CardioFlow, focused on transcatheter aortic-valve implantation, and MedBot, focused on surgical robotics, listed in Hong Kong in 2021. NeuroTech listed in Hong Kong and EverPace listed in Shanghai in 2022. The arrangement enabled the parent group to cover a broad range of therapeutic areas while allowing businesses such as structural heart, endovascular intervention, neurovascular therapy and electrophysiology to develop more specialized identities. The group continued investing in international capabilities. It established a regional subsidiary headquarters in California in 2022, incorporating manufacturing, innovation and regulatory functions. Its MedBot business developed the Toumai multi-port laparoscopic robot and pursued international clinical evaluations, including reported remote procedures involving Angola. MicroPort also maintained manufacturing and research operations in China, the United States, France and the United Kingdom. By 2025, MicroPort described itself as a diversified global medical-technology corporation with products distributed in more than 90 countries. The company reported more than 10 million cumulative coronary-stent shipments and implantations and announced a planned integration of CardioFlow with its CRM operations. Its evolution reflects a shift from a China-focused coronary-device company to a multi-platform group spanning cardiovascular intervention, structural heart, rhythm management, electrophysiology, endovascular and neurovascular therapy, orthopedics, critical care and surgical robotics.
- 2025
Coronary-stent milestone announced
[1]The company reports that cumulative global coronary-stent shipments and implantations each exceeded 10 million.
- 2022
NeuroTech and EverPace listings
[1]MicroPort NeuroTech lists in Hong Kong and MicroPort EverPace lists on the Shanghai STAR Market.
- 2021
CardioFlow and MedBot listings
[1]MicroPort CardioFlow and MicroPort MedBot complete Hong Kong listings.
- 2020
Endovastec lists in Shanghai
[1]MicroPort Endovastec becomes a listed company on the Shanghai STAR Market.
- 2018
CRM and Lombard transactions
[1]MicroPort acquires LivaNova’s CRM business and Lombard Medical Technologies’ endovascular operations.
- 2015
Firehawk receives European CE Mark
[1]Firehawk gains European regulatory clearance through CE Mark certification.
- 2014
OrthoRecon acquisition
[1]MicroPort acquires Wright Medical’s OrthoRecon business and enters large-joint reconstruction at scale.
- 2014
Firehawk receives Chinese approval
[1]The Firehawk drug-eluting stent receives regulatory approval in China.
- 2010
Hong Kong stock-market listing
[1]MicroPort completes its initial public offering on the Hong Kong Stock Exchange.
- 2004
Firebird platform launches
[1]MicroPort introduces the Firebird drug-eluting coronary-stent platform during its early domestic expansion.
Products and positioning
A diversified, innovation-led medical-technology group combining Chinese-origin product development with global manufacturing, clinical research and commercialization across cardiovascular, orthopedic, endovascular and robotic-surgery markets.
Drug-eluting coronary stent · 2004
Firebird
Firebird is a family of drug-eluting coronary stents that formed a central part of MicroPort’s early interventional-cardiology business. The platform was developed for percutaneous coronary intervention and helped the company establish a leading position in China before broader international expansion.
Targeted drug-eluting coronary stent
Firehawk
Firehawk is a coronary stent designed to deliver sirolimus from recessed grooves on the abluminal surface. Its biodegradable-polymer architecture and targeted drug delivery approach are intended to reduce the amount of drug and polymer while maintaining protection against restenosis.
Bioresorbable vascular scaffold
Firesorb
Firesorb is MicroPort’s bioresorbable vascular-scaffold platform. It belongs to a technology category that attracted substantial industry interest but also faced clinical and commercial setbacks among early-generation products, making ongoing development and clinical evaluation an important part of its positioning.
Transcatheter aortic-valve implantation system
VitaFlow and VitaFlow Liberty
VitaFlow and VitaFlow Liberty are structural-heart systems developed by MicroPort CardioFlow for transcatheter aortic-valve implantation. They address aortic-valve disease through catheter-based valve replacement and form the core of MicroPort’s structural-heart platform.
Multi-port laparoscopic surgical robot
Toumai Surgical Robot System
Toumai is a four-arm multi-port laparoscopic robotic system developed by MicroPort MedBot. It is intended for minimally invasive procedures in general, thoracic, urological and gynecological surgery, and has also been used in reported international remote-surgery evaluations.
Hip and knee reconstruction implants · 2014
MicroPort Orthopedics systems
MicroPort Orthopedics markets reconstruction products including the ADVANCE Medial-Pivot knee system, PROFEMUR hip systems, and DYNASTY and TRINITY hip-replacement implants. The business originated with the acquisition of Wright Medical’s OrthoRecon operations.
Endovascular aortic stent grafts
Altura and Aorfix
Altura and Aorfix are endovascular stent-graft platforms obtained through MicroPort’s acquisition of Lombard Medical Technologies. They are used in endovascular treatment of aortic disease, including aneurysm repair.
Controversies
Brand decisions
2025
Integrate CardioFlow with cardiac rhythm managementStrategyBackground
MicroPort aimed to create a more integrated global cardiovascular implantable-device platform.
Action taken
The company announced a merger of MicroPort CardioFlow with its CRM business in a transaction valued at approximately US$680 million.
Aftermath
The announced integration was intended to combine structural-heart and rhythm-management capabilities under a broader cardiovascular platform.
Transaction value. Approximately US$680 million (2025)
2018
Acquire LivaNova’s cardiac rhythm management businessM&ABackground
MicroPort sought to build a global cardiac rhythm management platform beyond its original coronary-intervention focus.
Action taken
The company acquired LivaNova’s CRM business, including pacemakers, defibrillators, cardiac-resynchronization products and associated leads.
Aftermath
The transaction established Clamart, France, as a major CRM headquarters and manufacturing location within the group.
Acquisition value. Approximately €190 million (2018)
Recent events
- 2025
MicroPort reports coronary stent milestone and cardiovascular integration plans[1]
Product generation
MicroPort reported that cumulative global coronary-stent shipments and implantations had each passed 10 million and announced plans to integrate CardioFlow with its CRM business.
- 2022
MicroPort NeuroTech and MicroPort EverPace complete listings[1]
Other
NeuroTech listed in Hong Kong and EverPace listed on the Shanghai STAR Market, extending the group’s separately listed therapeutic platforms.
- 2021
MicroPort platforms complete multiple public listings[1]
Other
MicroPort CardioFlow and MicroPort MedBot listed in Hong Kong, expanding the group’s platform-based corporate and financing structure.
- 2020
MicroPort Endovastec lists on Shanghai STAR Market[1]
Other
The endovascular business became one of the early medical-device companies listed on the Shanghai Stock Exchange STAR Market.
- 2018
MicroPort acquires LivaNova cardiac rhythm management business[1]
M&A
The transaction added pacemakers, defibrillators, cardiac-resynchronization devices and related leads to MicroPort’s cardiovascular portfolio.
- 2014
MicroPort acquires Wright Medical OrthoRecon business[1]
M&A
The acquisition added hip and knee reconstruction products and established MicroPort Orthopedics as a major operating platform.
- 2010
MicroPort completes Hong Kong initial public offering[1]
Other
MicroPort completed its initial public offering on the Hong Kong Stock Exchange under stock code 00853.HK.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/microport · Editorial policy · How profiles are compiled